News

Just announced! Research funding award for up t...
RETpositive is thrilled to announce the call for applications to award both a $200,000 grant as well as a one million dollar funding award for medical research specifically looking at...
Just announced! Research funding award for up t...
RETpositive is thrilled to announce the call for applications to award both a $200,000 grant as well as a one million dollar funding award for medical research specifically looking at...

The RET advocacy community grows with launch of...
RETpositive is excited to announce another key addition to the RET community: The Happy Lungs Project! We have had initial discussions about collaborating on RET specific medical research and other...
The RET advocacy community grows with launch of...
RETpositive is excited to announce another key addition to the RET community: The Happy Lungs Project! We have had initial discussions about collaborating on RET specific medical research and other...

Selpercatinib and Pralsetinib continue to make ...
Both of the recently FDA approved first generation, selective RET inhibitors Selpercatinib (Retevmo) and Pralsetinib (Gavreto) continued to garner attention at this years American Society of Clinical Oncology (ASCO) conference...
Selpercatinib and Pralsetinib continue to make ...
Both of the recently FDA approved first generation, selective RET inhibitors Selpercatinib (Retevmo) and Pralsetinib (Gavreto) continued to garner attention at this years American Society of Clinical Oncology (ASCO) conference...

Early results on another selective RET inhibito...
BOS172738 was already in trials since 2019 but we didn't know much about it. In the phase 1a results recently presented at ASCO 2021 they reported that their drug is...
Early results on another selective RET inhibito...
BOS172738 was already in trials since 2019 but we didn't know much about it. In the phase 1a results recently presented at ASCO 2021 they reported that their drug is...

Protein Degraders - New class of RET drugs in t...
Here we present new early-stage work being done on a completely new class of RET medications: protein degraders! This class has a lot of advantages over the current RET drugs:...
Protein Degraders - New class of RET drugs in t...
Here we present new early-stage work being done on a completely new class of RET medications: protein degraders! This class has a lot of advantages over the current RET drugs:...

No One Missed
Our partners at Lungevity have launched a campaign to promote comprehensive biomarker testing called No One Missed. This follows on our previous post on the importance of identifying genetic variants...
No One Missed
Our partners at Lungevity have launched a campaign to promote comprehensive biomarker testing called No One Missed. This follows on our previous post on the importance of identifying genetic variants...